Xilio Therapeutics Overview
- Year Founded
-
2016
- Status
-
Public
- Employees
-
76
- Stock Symbol
-
XLO
- Share Price
-
$8.07
- (As of Friday Closing)
Xilio Therapeutics General Information
Description
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.
Contact Information
Website
www.xiliotx.comCorporate Office
- 828 Winter Street
- Suite 300
- Waltham, MA 02451
- United States
Corporate Office
- 828 Winter Street
- Suite 300
- Waltham, MA 02451
- United States
Xilio Therapeutics Stock Performance
As of 13-Nov-2026, Xilio Therapeutics’s stock price is $8.07. Its current market cap is $57M with 7.06M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $8.07 | $8.24 | $6.47 - $11.30 | $57M | 7.06M | 12.1K | -$0.22 |
Xilio Therapeutics Financials Summary
As of 30-Sep-2026, Xilio Therapeutics has a trailing 12-month revenue of $55M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | (70,187) | (62,890) | (9,183) | (30,238) |
| Revenue | 55,010 | 43,766 | 6,344 | 0 |
| EBITDA | (10,171) | (33,495) | (56,597) | (74,504) |
| Net Income | (11,490) | (35,036) | (58,241) | (76,404) |
| Total Assets | 134,832 | 154,685 | 71,075 | 60,926 |
| Total Debt | 5,960 | 6,954 | 8,142 | 12,504 |
Xilio Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Xilio Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Xilio Therapeutics Comparisons
Industry
Financing
Details
Xilio Therapeutics Competitors (2)
One of Xilio Therapeutics’s 2 competitors is Werewolf Therapeutics, a Formerly VC-backed company based in Waltham, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Werewolf Therapeutics | Formerly VC-backed | Waltham, MA | ||||
| Genetix Biotherapeutics | Private Equity-Backed | Somerville, MA |
Xilio Therapeutics Patents
Xilio Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2020139920-A2 | Activatable masked anti-ctla4 binding proteins | Inactive | 26-Dec-2018 | ||
| WO-2020139920-A3 | Activatable masked anti-ctla4 binding proteins | Inactive | 26-Dec-2018 | ||
| WO-2020139926-A2 | Anti-ctla4 antibodies and methods of use thereof | Inactive | 26-Dec-2018 | ||
| WO-2020139926-A3 | Anti-ctla4 antibodies and methods of use thereof | Inactive | 26-Dec-2018 | ||
| WO-2020069398-A1 | Masked cytokine polypeptides | Inactive | 27-Sep-2018 | C07K14/55 |
Xilio Therapeutics Signals
Xilio Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Xilio Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
37.23 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Xilio Therapeutics FAQs
-
When was Xilio Therapeutics founded?
Xilio Therapeutics was founded in 2016.
-
Where is Xilio Therapeutics headquartered?
Xilio Therapeutics is headquartered in Waltham, MA.
-
What is the size of Xilio Therapeutics?
Xilio Therapeutics has 76 total employees.
-
What industry is Xilio Therapeutics in?
Xilio Therapeutics’s primary industry is Drug Discovery.
-
Is Xilio Therapeutics a private or public company?
Xilio Therapeutics is a Public company.
-
What is Xilio Therapeutics’s stock symbol?
The ticker symbol for Xilio Therapeutics is XLO.
-
What is the current stock price of Xilio Therapeutics?
As of 13-Nov-2026 the stock price of Xilio Therapeutics is $8.07.
-
What is the current market cap of Xilio Therapeutics?
The current market capitalization of Xilio Therapeutics is $57M.
-
What is Xilio Therapeutics’s current revenue?
The trailing twelve month revenue for Xilio Therapeutics is $55M.
-
Who are Xilio Therapeutics’s competitors?
Werewolf Therapeutics and Genetix Biotherapeutics are competitors of Xilio Therapeutics.
-
What is Xilio Therapeutics’s annual earnings per share (EPS)?
Xilio Therapeutics’s EPS for 12 months was -$0.22.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process